Ibuprofen vs. Acetaminophen: Which Fever Reducer is Right for You?
Explore the differences, uses, and safety of ibuprofen and acetaminophen for managing fever effectively.
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Haemoglobinuria: 48-Week Outcomes from APPLY-PNH and APPOINT-PNH Phase 3 Trials
Oral iptacopan provides sustained haemolysis control and improved haemoglobin in PNH patients over 48 weeks, with a favorable safety profile, supporting its role as a new therapeutic option.
Posted inClinical Updates news Rheumatology Specialties
Oral Regimens for Whipple’s Disease: A Non-Inferiority Trial of Doxycycline-Hydroxychloroquine Versus Standard Intravenous Therapy
A German phase 2/3 trial found oral doxycycline-hydroxychloroquine as effective and safe as standard intravenous ceftriaxone followed by oral trimethoprim-sulfamethoxazole for Whipple’s disease, potentially transforming outpatient management.
Dissecting Depression in Diabetes: Distinct Links of Somatic and Cognitive Symptoms with Inflammation and Insulin Resistance
New GRADE sub-study reveals that somatic symptoms of depression, not cognitive-affective symptoms, are chiefly associated with inflammation and insulin resistance in type 2 diabetes, highlighting a pathophysiological bridge for targeted interventions.
Seasonal Malaria Chemoprevention in Uganda: Efficacy of SPAQ and Dihydroartemisinin-Piperaquine in the Era of Drug Resistance
A large cluster-randomised trial in Uganda demonstrates that both SPAQ and dihydroartemisinin-piperaquine are highly effective and safe for seasonal malaria chemoprevention in children, with no evidence of resistance selection.
Posted inClinical Updates news Oncology Specialties
Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial
The KOMET phase 3 trial shows selumetinib offers significant tumor response in adults with NF1 and inoperable plexiform neurofibromas, with a manageable safety profile.
Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?
Relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer, with a favorable safety profile, suggesting a potential new treatment standard.
Posted inClinical Updates news Orthopedics Specialties
Surgery Versus Corticosteroid Injection for Carpal Tunnel Syndrome: Insights from the DISTRICTS Randomised Controlled Trial
The DISTRICTS trial demonstrates that initial surgical treatment for carpal tunnel syndrome leads to significantly higher recovery rates at 18 months compared to starting with corticosteroid injections, despite similar adverse event profiles.
Posted inClinical Updates news Oncology Specialties
Retifanlimab Plus Carboplatin-Paclitaxel: A New Standard for Advanced Squamous Cell Anal Cancer?
Retifanlimab combined with carboplatin-paclitaxel significantly prolongs progression-free survival in advanced squamous cell anal cancer, offering a promising new first-line standard of care.
Posted inClinical Updates news Oncology Specialties
First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial
The IMforte phase 3 trial demonstrates that lurbinectedin plus atezolizumab as first-line maintenance significantly prolongs progression-free and overall survival in extensive-stage small-cell lung cancer, albeit with increased hematologic toxicity.
Posted inAI Clinical Updates General Surgery news Specialties
Online Video Versus Face-to-Face Preoperative Consultation for Major Abdominal Surgery: Insights from the VIDEOGO Non-Inferiority Trial
The VIDEOGO trial shows that online video consultations are non-inferior to face-to-face consultations for preoperative assessment in major abdominal surgery, achieving similar patient satisfaction and information recall.
Targeted Pneumococcal Vaccination in New Older Adult Care Home Residents: Evidence from National Surveillance in England
Vaccinating new older adult care home residents with PCV20 or PPV23 could prevent substantially more invasive pneumococcal disease cases and deaths per dose than standard age-based vaccination, supporting policy revision.
Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial
A 4-year phase 3 extension study shows that anifrolumab improves patient-reported outcomes and quality of life in systemic lupus erythematosus, with a favorable safety profile.
Posted inClinical Updates news Oncology Radiology Specialties Urology
Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial
The PACE-C phase 3 trial shows that stereotactic body radiotherapy (SBRT) and moderately hypofractionated radiotherapy (MHRT) have comparable early toxicity profiles in intermediate- and high-risk prostate cancer patients.
Posted inClinical Updates news Oncology Specialties
Ten-Year Outcomes of Partial-Breast Radiotherapy After Breast Conservation Surgery: Insights from the UK IMPORT LOW Trial
The IMPORT LOW trial confirms that partial-breast and reduced-dose radiotherapy are as effective and safe as whole-breast radiotherapy for selected women with early breast cancer, supporting their use as standard care.
Posted inClinical Updates news Psychiatry Specialties
Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia
Weekly LYN-005 demonstrated pharmacokinetic equivalence to daily risperidone, sustained therapeutic levels, and manageable safety in clinically stable patients, offering a novel option to address non-adherence in schizophrenia.
Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia
Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.
Posted inClinical Updates HIV/AIDS news Specialties
Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial
The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.
Posted inClinical Updates news Oncology Specialties
Zanidatamab Plus Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastro-Oesophageal Adenocarcinoma: Clinical Efficacy and Safety Insights from a Phase 2 Study
Zanidatamab combined with chemotherapy shows promising efficacy and manageable safety in first-line treatment of HER2-positive advanced gastro-oesophageal adenocarcinoma, with durable responses and improved survival outcomes.
Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results
The combination of bexmarilimab and azacitidine shows manageable safety and promising efficacy in high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukaemia, supporting further investigation.